Johnson A G, Seideman P, Day R O
Department of Clinical Pharmacology and Toxicology, St Vincent's Hospital, Sydney, New South Wales, Australia.
Drug Saf. 1993 Feb;8(2):99-127. doi: 10.2165/00002018-199308020-00002.
The prevalence and incidence of adverse drug interactions involving nonsteroidal anti-inflammatory drugs (NSAIDs) remains unknown. To identify those proposed drug interactions of greatest clinical significance, it is appropriate to focus on interactions between commonly used and/or commonly coprescribed drugs, interactions for which there are numerous well documented case reports in reputable journals, interactions validated by well designed in vivo human studies and those affecting high-risk drugs and/or high-risk patients. While most interactions between NSAIDs and other drugs are pharmacokinetic, NSAID-related pharmacodynamic interactions may be considerably more important in the clinical context, and prescriber ignorance is likely to be a major determinant of many adverse drug interactions. Prescribing NSAIDs is relatively contraindicated for patients on oral anticoagulants due to the risk of haemorrhage, and for patients taking high-dose methotrexate due to the dangers of bone marrow toxicity, renal failure and hepatic dysfunction. Combination NSAID therapy cannot be justified as toxicity may be increased without any improvement in efficacy. Where lithium or anti-hypertensives are coprescribed with NSAIDs, close monitoring is mandatory for lithium toxicity and hypertension, respectively, and aspirin (acetylsalicylic acid) or sulindac are preferred. Phenytoin or oral hypoglycaemic agents may be administered with NSAIDs other than pyrazoles and salicylates provided that patients are monitored carefully at the initiation and cessation of NSAID treatment. Digoxin, aminoglycosides and probenecid may be coprescribed with NSAIDs, but close monitoring is required, particularly for high-risk patients such as the elderly. Indomethacin and triamterene should be avoided due to the risk of renal failure. High dose aspirin should be replaced by naproxen in patients on valproic acid (sodium valproate) and care is required when corticosteroids are administered to patients taking salicylates long term in high dosage. Interactions between NSAIDs and antacids or cholestyramine are generally avoidable. Adverse drug interactions involving NSAIDs may be limited by rational prescribing and by careful monitoring, particularly for high-risk patients, drugs and therapy periods.
涉及非甾体抗炎药(NSAIDs)的药物不良相互作用的患病率和发病率尚不清楚。为了确定那些具有最大临床意义的药物相互作用,应关注常用和/或常用联合处方药物之间的相互作用、在知名期刊上有大量充分记录的病例报告的相互作用、经精心设计的人体体内研究验证的相互作用以及那些影响高危药物和/或高危患者的相互作用。虽然NSAIDs与其他药物之间的大多数相互作用是药代动力学的,但在临床背景下,NSAID相关的药效学相互作用可能更为重要,而处方医生的无知可能是许多药物不良相互作用的主要决定因素。由于出血风险,口服抗凝剂患者相对禁忌使用NSAIDs;由于存在骨髓毒性、肾衰竭和肝功能障碍的风险,服用高剂量甲氨蝶呤的患者也禁忌使用。联合使用NSAIDs治疗不合理,因为可能会增加毒性而疗效无任何改善。当锂或抗高血压药与NSAIDs联合处方时,分别必须密切监测锂中毒和高血压情况,且首选阿司匹林(乙酰水杨酸)或舒林酸。除吡唑类和水杨酸盐外,苯妥英或口服降糖药可与NSAIDs合用,但在NSAID治疗开始和停止时需仔细监测患者。地高辛、氨基糖苷类和丙磺舒可与NSAIDs联合处方,但需要密切监测,尤其是对于老年人等高风险患者。由于存在肾衰竭风险,应避免使用吲哚美辛和氨苯蝶啶。服用丙戊酸(丙戊酸钠)的患者应将高剂量阿司匹林替换为萘普生,长期高剂量服用水杨酸盐的患者使用皮质类固醇时需谨慎。NSAIDs与抗酸剂或考来烯胺之间的相互作用通常是可以避免的。涉及NSAIDs的药物不良相互作用可通过合理处方和仔细监测来限制,特别是对于高风险患者、药物和治疗期。